242 related articles for article (PubMed ID: 19723666)
1. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.
Bhagwat NR; Roginskaya VY; Acquafondata MB; Dhir R; Wood RD; Niedernhofer LJ
Cancer Res; 2009 Sep; 69(17):6831-8. PubMed ID: 19723666
[TBL] [Abstract][Full Text] [Related]
2. Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297.
Arbogast S; Behnke S; Opitz I; Stahel RA; Seifert B; Weder W; Moch H; Soltermann A
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):99-105. PubMed ID: 21030862
[TBL] [Abstract][Full Text] [Related]
3. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
[TBL] [Abstract][Full Text] [Related]
7. Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients.
Ahmad A; Enzlin JH; Bhagwat NR; Wijgers N; Raams A; Appledoorn E; Theil AF; J Hoeijmakers JH; Vermeulen W; J Jaspers NG; Schärer OD; Niedernhofer LJ
PLoS Genet; 2010 Mar; 6(3):e1000871. PubMed ID: 20221251
[TBL] [Abstract][Full Text] [Related]
8. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks.
Niedernhofer LJ; Odijk H; Budzowska M; van Drunen E; Maas A; Theil AF; de Wit J; Jaspers NG; Beverloo HB; Hoeijmakers JH; Kanaar R
Mol Cell Biol; 2004 Jul; 24(13):5776-87. PubMed ID: 15199134
[TBL] [Abstract][Full Text] [Related]
9. The formation of UV-induced chromosome aberrations involves ERCC1 and XPF but not other nucleotide excision repair genes.
Chipchase MD; Melton DW
DNA Repair (Amst); 2002 Apr; 1(4):335-40. PubMed ID: 12509251
[TBL] [Abstract][Full Text] [Related]
10. ERCC1-XPF targeting to psoralen-DNA crosslinks depends on XPA and FANCD2.
Sabatella M; Pines A; Slyskova J; Vermeulen W; Lans H
Cell Mol Life Sci; 2020 May; 77(10):2005-2016. PubMed ID: 31392348
[TBL] [Abstract][Full Text] [Related]
11. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
Kirschner K; Melton DW
Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
[TBL] [Abstract][Full Text] [Related]
12. XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
Hatch SB; Swift LP; Caporali S; Carter R; Hill EJ; MacGregor TP; D'Atri S; Middleton MR; McHugh PJ; Sharma RA
Int J Cancer; 2014 Mar; 134(6):1495-503. PubMed ID: 23982883
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
[TBL] [Abstract][Full Text] [Related]
14. Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation.
Wang J; He H; Chen B; Jiang G; Cao L; Jiang H; Zhang G; Chen J; Huang J; Yang B; Zhou C; Liu T
Nat Commun; 2020 Feb; 11(1):786. PubMed ID: 32034146
[TBL] [Abstract][Full Text] [Related]
15. ERCC1-XPF endonuclease facilitates DNA double-strand break repair.
Ahmad A; Robinson AR; Duensing A; van Drunen E; Beverloo HB; Weisberg DB; Hasty P; Hoeijmakers JH; Niedernhofer LJ
Mol Cell Biol; 2008 Aug; 28(16):5082-92. PubMed ID: 18541667
[TBL] [Abstract][Full Text] [Related]
16. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
[TBL] [Abstract][Full Text] [Related]
17. A novel antibody-based approach to detect the functional ERCC1-202 isoform.
Kuo MS; Adam J; Dorvault N; Robin A; Friboulet L; Soria JC; Olaussen KA
DNA Repair (Amst); 2018 Apr; 64():34-44. PubMed ID: 29482102
[TBL] [Abstract][Full Text] [Related]
18. The ERCC1 and ERCC4 (XPF) genes and gene products.
Manandhar M; Boulware KS; Wood RD
Gene; 2015 Sep; 569(2):153-61. PubMed ID: 26074087
[TBL] [Abstract][Full Text] [Related]
19. Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody.
Smith DH; Fiehn AM; Fogh L; Christensen IJ; Hansen TP; Stenvang J; Nielsen HJ; Nielsen KV; Hasselby JP; Brünner N; Jensen SS
Sci Rep; 2014 Mar; 4():4313. PubMed ID: 24603753
[TBL] [Abstract][Full Text] [Related]
20. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]